These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 18451237

  • 1. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225.
    Clin Cancer Res; 2008 May 01; 14(9):2717-25. PubMed ID: 18451237
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 3. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
    Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G, Innovative Therapies for Children with Cancer European Consortium.
    Eur J Cancer; 2009 Sep 01; 45(13):2342-51. PubMed ID: 19362466
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.
    J Clin Oncol; 2005 Jan 20; 23(3):585-90. PubMed ID: 15659505
    [Abstract] [Full Text] [Related]

  • 5. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
    Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Clin Cancer Res; 2009 Jun 15; 15(12):4191-8. PubMed ID: 19509155
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.
    Cancer; 2005 May 15; 103(10):2128-31. PubMed ID: 15812822
    [Abstract] [Full Text] [Related]

  • 7. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.
    Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971
    [Abstract] [Full Text] [Related]

  • 8. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 01; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 9. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Mar 01; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 10. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.
    Pathol Res Pract; 2007 Mar 01; 203(3):127-34. PubMed ID: 17298867
    [Abstract] [Full Text] [Related]

  • 11. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ.
    J Clin Oncol; 2005 Feb 10; 23(5):982-9. PubMed ID: 15572730
    [Abstract] [Full Text] [Related]

  • 12. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA.
    Anticancer Res; 2010 Feb 10; 30(2):547-52. PubMed ID: 20332468
    [Abstract] [Full Text] [Related]

  • 13. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 10; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 14. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    Oncology; 2009 Sep 10; 76(5):326-32. PubMed ID: 19307738
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.
    N Engl J Med; 2002 Aug 15; 347(7):472-80. PubMed ID: 12181401
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
    Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA.
    Breast Cancer Res Treat; 2005 Mar 15; 90(2):157-63. PubMed ID: 15803362
    [Abstract] [Full Text] [Related]

  • 17. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
    Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E.
    Eur J Cancer; 2009 Sep 15; 45(13):2352-9. PubMed ID: 19505817
    [Abstract] [Full Text] [Related]

  • 18. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 15; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 20. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2005 Feb 01; 23(4):866-73. PubMed ID: 15681532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.